Charlene A. Banard - 14 Dec 2022 Form 3 Insider Report for Atara Biotherapeutics, Inc. (ATRA)

Role
EVP, Chief Technical Officer
Signature
/s/ Jeff Kiekhofer, Attorney-in-Fact for Charlene A. Banard
Issuer symbol
ATRA
Transactions as of
14 Dec 2022
Net transactions value
$0
Form type
3
Filing time
16 Dec 2022, 16:43:11 UTC
Previous filing
26 May 2022
Next filing
03 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ATRA Common Stock 155,350 14 Dec 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ATRA Employee Stock Option (Right to Buy) 14 Dec 2022 Common Stock 292,023 $7.29 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to these restricted stock units ("RSUs") vest on May 15, 2023, and 1/16th of the total number of shares subject to the RSUs vest on each of the next 12 Quarterly Vesting Dates (as defined herein), subject to the reporting person's continuous service. "Quarterly Vesting Date" means March 1, May 15, August 15 and November 15 of each year, provided that if such date falls on a weekend or holiday, the Quarterly Vesting Date shall be the first (1st) business day after such date.
F2 25% of the shares subject to the option vest on April 25, 2023, and the remaining shares vest in equal monthly installments over the following 36 months, subject to the reporting person's continuous service.

Remarks:

Exhibit 24 - Power of Attorney